Rodríguez-Nogales, AlbaGálvez, Julio2023-02-092023-02-092020-11-09Rodríguez-Nogales A, Gálvez J. Targeting gut microbiome, is it always a therapeutic option? EBioMedicine. 2020 Dec;62:103099. doi: 10.1016/j.ebiom.2020.103099.2352-3964http://hdl.handle.net/10668/16566Obstructive sleep apnea (OSA) is a common respiratory disorder associated with cardiovascular comorbidities and cancer due to chronic intermittent hypoxia (CIH). This condition affects the gut microbiome, altering its diversity and increasing intestinal permeability, which contributes to insulin resistance. Dysbiosis is linked to chronic diseases such as metabolic syndrome and cardiovascular disorders.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Obstructive sleep apnea (OSA)Chronic intermittent hypoxia (CIH)Gut microbiomeOxidative stressInsulin resistanceAnimalsDisease ManagementDisease SusceptibilityGastrointestinal MicrobiomeHumansPrecision Medicineresearch article33161230open accessApnea obstructiva del sueño (AOS)Hipoxia intermitente crónica (HIC)Disbiosis del microbioma intestinalSistema nervioso simpáticoEnfermedades cardiovasculares y comorbilidades10.1016/j.ebiom.2020.1030992352-3964PMC7656137https://doi.org/10.1016/j.ebiom.2020.103099https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656137/pdf